Format

Send to

Choose Destination
AIDS Res Hum Retroviruses. 2017 Mar 2. doi: 10.1089/aid.2016.0202. [Epub ahead of print]

Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations.

Author information

1
1 Department of Medicine, University of California , San Francisco, San Francisco, California.
2
2 Department of Epidemiology and Biostatistics, University of California , San Francisco, San Francisco, California.
3
3 Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh , Pittsburgh, Pennsylvania.
4
4 Magee-Womens Research Institute , Pittsburgh, Pennsylvania.
5
5 Department of Bioengineering and Therapeutic Sciences, University of California , San Francisco, San Francisco, California.
6
6 University of Zimbabwe-University of California , San Francisco Collaborative Research Program, Harare, Zimbabwe .
7
7 Makerere University-Johns Hopkins University Research Collaboration , Kampala, Uganda .
8
8 FHI 360, Durham, North Carolina.
9
9 San Francisco Department of Public Health, Bridge HIV , San Francisco, California.
10
10 RTI International , Women's Global Health Imperative, San Francisco, California.
11
11 Department of Medicine, University of Alabama , Birmingham, Birmingham, Alabama.

Abstract

Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) prevented HIV acquisition among men and women in several trials and is broadly recommended. In the VOICE and FEM-PrEP trials, however, TDF/FTC-based PrEP did not prevent HIV acquisition among women in eastern and southern Africa. Tenofovir was detected in plasma, reflecting exposure and adherence in recent days, in fewer than one-third of participants. Drug concentrations in hair, which represent cumulative exposure and adherence over weeks to months, have never previously been examined among women on PrEP. We compared tenofovir hair concentrations among women assigned to oral TDF/FTC in the VOICE trial to those among men and transgender women enrolled in 2 open-label PrEP studies, the iPrEx open-label extension (OLE) study and the U.S. PrEP Demonstration Project (PrEP Demo). Tenofovir hair concentrations were detectable in 55% of person-visits in VOICE, 75% of person-visits in iPrEx OLE (pā€‰=ā€‰.006), and 98% of person-visits in PrEP Demo (pā€‰<ā€‰.001). Median tenofovir hair concentrations corresponded to an estimated 0.2, 2.9, and 6.0 TDF/FTC doses taken per week in the three studies, respectively. In VOICE, combining tenofovir concentration data from plasma and hair suggested inconsistent, low-level product use. Incorporation of both short- and long-term adherence measures may allow for an improved understanding of patterns of drug-taking among women during global PrEP roll-out.

KEYWORDS:

HIV and women; HIV prevention; PrEP Demo; VOICE; adherence monitoring; hair concentrations; iPrEx OLE; plasma concentrations; pre-exposure prophylaxis

PMID:
28253024
PMCID:
PMC5564054
[Available on 2018-08-01]
DOI:
10.1089/aid.2016.0202

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center